Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | 12-2012 | 12-2011 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -52,448 | -58,259 | -44,863 | N/A |
| Depreciation Amortization | 6,226 | 9,504 | 7,117 | N/A |
| Accounts payable and accrued liabilities | 3,193 | 1,028 | -636 | N/A |
| Other Working Capital | -9,781 | -7,126 | -66 | N/A |
| Other Operating Activity | 5,052 | 15,939 | 10,035 | 0 |
| Operating Cash Flow | $-47,758 | $-38,914 | $-28,413 | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -6,477 | -319 | -150 | N/A |
| Other Investing Activity | 75 | 75 | 75 | 0 |
| Investing Cash Flow | $-6,402 | $-244 | $-75 | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 21,903 | 18,170 | 67,150 | N/A |
| Debt Repayment | -8,576 | -4,557 | -13,083 | N/A |
| Common Stock Issued | 18 | 7 | N/A | N/A |
| Other Financing Activity | 40,646 | 0 | 0 | 0 |
| Financing Cash Flow | $53,991 | $13,620 | $54,067 | $N/A |
| Beginning Cash Position | 4,083 | 29,621 | 4,042 | N/A |
| End Cash Position | 3,914 | 4,083 | 29,621 | N/A |
| Net Cash Flow | $-169 | $-25,538 | $25,579 | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -47,758 | -38,914 | -28,413 | N/A |
| Capital Expenditure | -6,477 | -319 | -150 | N/A |
| Free Cash Flow | -54,235 | -39,233 | -28,563 | 0 |